Home » Topics » Regulatory » EMA

EMA
RSS

EMA's CHMP grants positive opinion for dupixent for the treatment of atopic dermatitis

July 24, 2017

EMA committee recommends approval of label update for Lixiana

July 17, 2017

EMA validates pacritinib MAA for patients with myelofibrosis who have thrombocytopenia

July 14, 2017

Gilead Sciences' MAA for bictegravir/emtricitabine/tenofovir alafenamide FDC validated by EMA

July 14, 2017

ProQR Therapeutics receives orphan drug designations in E.U. and U.S. for QRX-411

July 7, 2017

RDD Pharma's RDD-0315 given orphan drug status in E.U.

July 7, 2017

Polatuzumab vedotin is eligible for access to EMA's PRIME program

June 30, 2017

Global Blood Therapeutics' GBT-440 obtains EMA PRIME designation

June 29, 2017

Stivarga for HCC approved in Japan, recommended for approval in E.U.

June 27, 2017

EC approves eslicarbazepine acetate monotherapy for newly diagnosed partial-onset epilepsy

June 26, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...